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A B S T R A C T
The aim of the study was to evaluate the efficacy of replacing current dual local ther-
apy (timolol and pilocarpine) with latanoprost 0.005% in 71 pseudoexfoliation glau-
coma patients with controlled intraocular pressure (IOP). 39 patients switched to lata-
noprost 0.005%) and 32 patients continued timolol-pilocarpine therapy. Mean diurnal
(IOP) was measured at baseline, after 0.5, 1, 3 and 6 months of treatment. After 6 months
38 patients with latanoprost and 30 patients with timolol-pilocarpine had completed
the study. At baseline the mean diurnal IOP was 20.4±2.0 mmHg for patients in lata-
noprost treatment group and 21.4±2.1 mmHg for patients in timolol- pilocarpine group.
At the end of the study, after 6 months of treatment, the mean diurnal IOP values were
16.6±2.4 and 17.9±2.0 mmHg respectively. IOP was statistically significantly reduced
from baseline (p<0.001). The mean diurnal IOP change from baseline was –3.3±0.5 mmHg
(mean±SEM, ANCOVA) for the patients treated with latanoprost and –3.2±0.4 mmHg
for the patients treated with timolol+pilocarpine. This difference in IOP reduction be-
tween groups was not statistically significant (z=0.69; p= 0.49). This study showed that
combination therapy (timolol plus pilocarpine) in pseudoexfoliation glaucoma can effec-
tively be replaced by latanoprost monotherapy.
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Glaucoma is multifactorial syndrome
of progressive optic neuropathy charac-
terized by an unphysiological large cup/
disc ratio with reduced retinal sensitivity,
visual field defects and additional psy-
chophysical alterations1,2. In addition to
intraocular pressure (IOP), which is an
established risk factor, many other risk
factors have been described3–5. Evidence
suggests that higher mean IOP and high-
er peak IOP increase the risk of visual
field loss6,7. Latanoprost is a prostaglan-
din F2 analog and selective F-prosta-
glandin receptor agonists that effectively
reduce intraocular pressure (IOP) in pa-
tients with glaucoma8–10. In many pa-
tients topical  adrenergic antagonists
alone do not sufficiently lower IOP and
additional medications have to be pre-
scribed. Pilocarpine is frequently used as
»add on« therapy. The purpose of this
study was to evaluate the efficacy of re-
placing current dual therapy (-blocker
and pilocarpine) with latanoprost 0.005%
in pseudoexfoliation glaucoma.
Materials and Methods
This study included 71 pseudoexfolia-
tion glaucoma patients in a 6-month's
open-label comparison of latanoprost mo-
notherapy to the current dual therapy:
timolol and pilocarpine. After obtaining
approval from the appropriate regulatory
authorities and ethics committees, oral
consent was obtained from all patients
before entering the study. After a 4 week
run-in period on timolol 0.5% twice daily
and pilocarpine 2% three times a day, the
patients were randomized to two parallel
study groups: one group switched from
timolol and pilocarpine to latanoprost,
0.005% once daily in the evening (39 pa-
tients), while the other group continued
on timolol and pilocarpine (32 patients).
The study protocol followed the guide-
lines of the Declaration of Helsinki.
All participants, aged 51–75 (mean
61.1±5.2 years), enrolled in study were
diagnosed as suffering of pseudoexfolia-
tion glaucoma, based on having control-
led IOP on current local therapy (IOP21
mmHg), open angle on gonioscopy with
dandrufflike flakes of exfoliation mate-
rial, exfoliation material on the pupillary
margin and on the anterior lens surface.
No evidence of underlying ocular or sys-
temic cause of high IOP, glaucomatous vi-
sual field defect and papillary excavation
(C/D vertical > 0.3). The patients were in-
cluded in the study by the judgment of
the investigator based of the disease sta-
tus of each individual patient. Exclusion
criteria included any treatment with more
than two glaucoma medications and any
previous treatment with latanoprost, cur-
rent use of contact lenses, previous filter-
ing surgery, argon laser trabeculoplasty,
pregnant women and any ocular inflam-
mation within three months were rea-
sons for excluded from study. The pa-
tients were examined at a prestudy visit
within 4 weeks of trial treatment initia-
tion. Table 1 presents the schedule of ex-
aminations. Intraocular pressure was
measured by Goldmann applanation to-
nometer. In each eye three measurements
were performed and the mean of the three
measurements was used in the statistical
analyses. IOP were recorded at baseline
and 15 days, 1 months, 3 months and 6
months after the initiation of latanoprost.
Examinations were done at 9 a.m., 1 p.m.
and 6 p.m. and the diurnal IOP was cal-
culated.
Statistical analysis was performed us-
ing Statistica for Windows (Stat Soft Inc,
USA, and Version 6.0). All data were ana-
lyzed by a descriptive analysis. Compari-
sons between the groups were made us-
ing the non-parametric Mann-Whitney U
test. An analysis of covariance (ANCO-
VA) was performed with diurnal IOP
changes at months 6 from baseline as re-
sponse variable, baseline diurnal IOP as
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covariate and group as factors. We also
used Wilcoxon matched pairs test to com-
pare baseline and post-treatment IOP at
each point of measurement for each
group. A 95% confidence interval vas cal-
culated for the difference in mean IOP re-
duction between the treatment groups. A
Chi-square test and Students t-test were
used to compare patient data such as sex
and age. Findings with an error probabil-
ity value of < 0.05 were considered to be
statistically significant.
Results
Of 71 pseudoexfoliation glaucoma pa-
tients included in study, 39 patients were
consisted the latanoprost treatment group
and 32 the timolol-pilocarpine group. The
demographic characteristic is presented
in Table 2. One of the patients from the
latanoprost treatment group was with-
drawn before the study termination be-
cause of the lost of follow up. Two pa-
tients from the timolol-pilocarpine treat-
ment group were withdrawn because of
headache.
At baseline the mean diurnal IOP was
20.4±2.0 mmHg (mean±SD) for patients
in latanoprost treatment group and 21.4±
2.1 mmHg for patients in the timolol-pilo-
carpine group. At the end of the study, af-
ter 6 months of treatment, the mean IOP
values were 16.6±2.4 and 17.9±2.0 mm
Hg, in the two groups respectively.
The mean IOP at each measurement
for the treatment groups is presented in
Table 3. Compared with baseline mea-
surements the mean IOP reduction at 6
months was statistically significant in both
treatment groups (p<0.001). The changes
in mean diurnal IOP from baseline to the
6 months for the two groups determined
with ANCOVA are shown in Figure 1. The
mean diurnal IOP change from baseline
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of the therapy (months)Examinations Four weeks Baseline
0.5 1 3 6
before baseline
Gonioscopy X
Visual field X X
Ophthalmoscopy X X X X X X
Visual acuity X X X X X X
Adverse events X X X X X X
Slit-lamp examination X X X X X X
Intraocular pressure X X X X X X
TABLE 2
DEMOGRAFIC DATA OF ALL PATIENT
Group Latanoprost Timolol-pilocarpine p
Number of patients 38 30
Mean age (±SD) 60.3±4.9 62.2±5.4 0.1a
Sex (male/female) 17/21 14/16 0.8b
aStudent’s t-test; bChi-square test
was –3.3±0.5 mmHg, (mean±SEM, AN-
COVA), 95% CI (–4.2±2.4) mmHg, for the
patients treated with latanoprost and
–3.2±0.4 mmHg, 95% CI (–4.0±2.4) mm
Hg for the patients treated with timo-
lol+pilocarpine. Switching from timolol
-pilocarpine to latanoprost once daily
caused statistically not significant reduc-
tion in mean diurnal IOP (z=0.21; p=
0.84). The change in treatment in these
groups caused a reduction corresponding
to 16% for latanoprost and 15% for ti-
molol-pilocarpine. This difference in IOP
reduction between groups was not statis-
tically significant (z=0.69; p=0.49).
No systemic adverse event was repor-
ted. Adverse ocular events in latanoprost
group was reported by 9 patients (23.7%),
conjunctival hyperemia in 4 (10.5%), itch-
ing in 4 (10.5%) and increase iris pigmen-
tation in 1 (2.6%) patients. In the timo-
lol-pilocarpine group adverse ocular ef-
fects was reported in 8 (21%) patients:
eye irritation in 5 (16.7%) and headache
in 3 (10%) patients.
Discussion
Combination of two topical medications
is common in the treatment of glaucoma.
A topical medication that reduces inflow
such as -adrenergic antagonist prefera-
bly is combined with medication that in-
crease outflow such as pilocarpine and
latanoprost. It is a great importance to
consider the option of switching a patient
from multiple dosing regiments to mo-
notherapy. In our study, patients with
pseudoexfoliation glaucoma on current
dual therapy with topical -adrenergic
antagonists in combination with pilocar-
pine, were switched to treatment with
latanoprost once daily. Mean diurnal IOP
was considered a relevant measure of cli-
nical efficacy for comparing these two
treatment groups after 6 months of ther-
apy. The results of the study showed that
latanoprost 0.005% applied topically once
daily is at least as effective in reducing
the IOP as timolol-pilocarpine. Similar
results were found in other studies11–15
although IOP reducing effect was some-
thing less marked in our patients. Swi-
tching from the timolol-pilocarpine to la-
tanoprost reduced mean diurnal IOP by
16%. IOP reducing effect in the timo-
lol-pilocarpine group was 15%. This dif-
ference in IOP reduction between the two
groups was not statistically significant
(p=0.49). A multicenter randomized 6-
week trial of 237 glaucoma patients con-
ducted in France and Sweden showed
that latanoprost monotherapy was at least
as effective as therapy with the fixed
combination of timolol and pilocarpine in
reducing mean diurnal IOP15. Although
our study compared two relatively small
groups and the previous studies did not
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TABLE 3
MEAN VALUES (±SD) OF IOP (mmHg) IN
LATANOPROST AND TIMOLOL-PILOCARPINE





Baseline 20.4 (2.0) 21.4 (2.1)
15 days 17.1 (1.6) 18.1 (1.7)
1 months 16.7 (1.6) 18.0 (1.8)
3 months 16.4 (1.8) 18.2 (1.9)













































Least square means (ANCOVA)
Fig. 1. Diurnal IOP reduction (mean±SEM) after
6 months compared with baseline values.
detect differences as well, the power of
the study was enough to detect signifi-
cant differences.
This study showed that latanoprost
0.005% applied topically once daily is ef-
fective in reducing the IOP as combina-
tion timolol-pilocarpine and this dual the-
rapy (timolol plus pilocarpine) in pseudo-
exfoliation glaucoma can effectively be re-
placed by latanoprost monotherapy in
many patients. The convience of daily ad-
ministration of a single drop of latano-
prost versus multiple drops of timolol and
pilocarpine can improve patient compli-
ance too.
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ISPITIVANJE ZAMJENE TIMOLOLA I PILOKARPINA S
LATANOPROSTOM KOD PSEUDOEKSFOLIJATIVNOG GLAUKOMA
S A @ E T A K
Cilj ove studije bio je ispitati efikasnost zamjene dvojne lokalne terapije (timolol i
pilokarpin) kod 71-og bolesnika s pseudoeksfolijativnim glaukomom s reguliranim in-
traokularnim tlakom (IOT). Kod 39 bolesnika uveden je u terapiji latanoprost 0.005%,
a ostala 32 bolesnika su nastavila sa svojom po~etnom terapijom (timolol i pilokarpin).
Srednji dnevni IOT mjeren je na po~etku, 0.5, 1, 3 i 6 mjeseci. Nakon 6 mjeseci, 38
bolesnika s latanoprostom i 30 sa timololom i pilokarpinom zavr{ila su ispitivanje. Po-
~etna srednja dnevna vrijednost IOT-a bila je 20.4±2.0 mmHg kod bolesnika s lata-
noprostom u terapiji, a 21.4±2.0 mmHg kod bolesnika s timololom i pilokarpinom. Na-
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kon 6 mjeseci srednja vrijednost dnevnog IOT-a bila je 16.6±2.4 mm Hg odnosno 17.9
±2.0 mmHg. Ovo sni`enje IOT-a bilo je statisti~ki zna~ajno (p<0.001). Srednja vrijed-
nost promjene IOT-a bila je –3.3±0.5 mmHg (srednja vrijednost ±SEM, ANCOVA) kod
bolesnika s latanoprostom u terapiji, a –3.2±0.4 mmHg kod bolesnika s timololom i
pilokarpinom. Ova razlika u sni`enju IOT-a nije statisti~ki zna~ajna (z=0.69; p=0.49).
Ovo ispitivanje ukazuje da dvojna terapija (timolol i pilokarpin) kod pseudoeksfolija-
tivnog glaukoma mo`e biti uspje{no zamijenjena latanoprost monoterapijom.
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